Prion diseases: update on therapeutic patents (1999 – 2002)

Bibliography

• COLLINGE J: Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neuroscl (2001) 24:519–550.
   PubMed Web of Science ®Google Scholar
• PRUSINER SB: Shattuck lecture - neurodegenerative diseases and prions. N Engl. J. Med. (2001) 344:1516–1526.
   PubMed Web of Science ®Google Scholar
• AL-SHAHI R, WILL RG, WARLOW CP: Amount of research interest in rare and common neurological conditions: bibliometric study. Br. Med." (2001) 323:1461–1462.
   PubMedGoogle Scholar
• PROUT KA, LARNER AJ: Emerging therapeutic possibilities in prion diseases: patents 1993-1998. Exp. Opin. The]: Patents (1998) 8(9):1099–1108.
   Web of Science ®Google Scholar
• KNIGHT R: Therapeutic possibilities in CJD: patents 1996-1999. Exp. Opin. Thec Patents (2000) 10(1):49–57.
   Web of Science ®Google Scholar
• COLLINGE J, PALMER MS (Eds): Prion diseases. OUP, Oxford (1997).
   Google Scholar
• PRUSINER SB (Ed.): Prion biology and diseases. Cold Spring Harbor Laboratory Press, Cold Spring Harbor (1999).
   Google Scholar
• BROWN P: Transmissible spongiform encephalopathies. In: Early-onset dementia: a multidisciplinary approach. Hodges JR (Ed.), OUP, Oxford, UK (2001):367–384.
   Google Scholar
• PARCHI P, GAMBETTI P: Prion diseases and dementia. In: Molecular mechanisms of dementia. Wasco W, Tanzi RE (Eds), Humana, Totowa NJ, USA (1997):293–306.
   Google Scholar
• SY MS, GAMBETTI P, WONG BS: Human prion diseases. Med. Gin. North Am. (2002) 86:551–571.
   PubMedGoogle Scholar
• SCARAVILLI F, CORDERY RJ, KRETSCHMAR H et al.: Sporadic fatal insomnia: a case study. Ann. Neural (2000) 48:665–668.
   PubMed Web of Science ®Google Scholar
• KOVACS GG, TRABATTONI G, HAINFELLNER JA, IRONSIDE JW, KNIGHT RSG, BUDKA H: Mutations of the prion protein gene: phenotypic spectrum. J. Neurol (2002) 249:1567–1582.
   PubMed Web of Science ®Google Scholar
• GAJDUSEK DC: Unconventional viruses and the origin and disappearance of kuru. Science (1977) 197:943–960.
   PubMed Web of Science ®Google Scholar
• ZIGAS V: Laughing death: the untold story of kuru. Humana, Clifton NJ (1990).
   Google Scholar
• COLLINGE J: Variant Creutzfeldt-Jakob disease. Lancet (1999) 354:317–323.
   PubMedGoogle Scholar
• SPENCER MS, KNIGHT RSG, WILL RG: First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features. Br. Med. J. (2002) 324:1479–1482.
   PubMedGoogle Scholar
• MANNS D, BOUMAN W: CJD presenting with psychotic symptoms. Progress M Neurology and Psychiatry (2000) 4(6):29.
   Google Scholar
• PALMER MS, DRYDEN AJ, HUGHES JT, COLLINGE J: Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature (1991) 352:340–342.
   PubMed Web of Science ®Google Scholar
• FOX NC, FREEBOROUGH PA, MEKKAOUI KF, STEVENS JM, ROSSOR MN: Cerebral and cerebellar atrophy on serial magnetic resonance imaging in an initially symptom free subject at risk of familial prion disease. Br. Med. .1. (1997) 315:856–857.
   PubMedGoogle Scholar
• ZEIDLER M, SELLAR RJ, COLLIE DA et al: The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet (2000) 355:1412–1418.
   Google Scholar
• COLLIE DA, SELLARRJ, ZEIDLER M,COLCHESTER ACE KNIGHT R, WILL RG: MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol. an. Radial. (2001) 56:726–739.
   Google Scholar
• DA SILVA R, PATTERSON J, HADLEY D, RUSSELL A, TURNER M, ZEIDLER M: Single photon emission computed tomography in the identification of new variant Creutzfeldt-Jakob disease: case reports. Br. Med. J. (1998) 316:593–594.
   PubMedGoogle Scholar
• ZERR I, POCCHIARI M, COLLINS S et al: Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology (2000) 55:811–815.
   PubMed Web of Science ®Google Scholar
• TSCHAMPA HJ, NEUMANN M, ZERR I et al: Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease. J. Nemo]. Neurosurg. Psychiatry (2001) 71:33–39.
   PubMed Web of Science ®Google Scholar
• IRONSIDE J, LOWMAN A: The diagnosis of variant Creutzfeldt-Jakob disease. Adv. Gin. Neurosci. Rehabilitation (2002) 1(6):6–8.
   Google Scholar
• COLLINGE J, OWEN F, POULTER M et al.: Prion dementia without characteristic pathology. Lancet (1990) 336:7–9.
   PubMed Web of Science ®Google Scholar
• HILTON DA, FATHERS E, EDWARDS P, IRONSIDE JW, ZAJICEK J: Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet (1998) 352:703–704.
   PubMed Web of Science ®Google Scholar
• HILTON D, GHANI AC, CONYERS L et al.: Accumulation of prion protein in tonsil and appendix: review of tissue samples. Br. Med. J. (2002) 325:633–634.
   PubMedGoogle Scholar
• HILL AF, BUTTERWORTH RJ, JOINERS et al.: Investigation of variant Creutzfeldt-Jakob disease and other human prion disease with tonsil biopsy samples. Lancet (1999) 353:183–189.
   PubMed Web of Science ®Google Scholar
• HEGDE RS, TREMBLAY P, GROTH D, DEARMOND SJ, PRUSINER SB, LINGAPPA VR: Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature (1999) 402:822–826.
   PubMed Web of Science ®Google Scholar
• COLLINGE J, WHITTINGTON MA, SIDLE KCL et at Prion protein is necessary for normal synaptic function. Nature (1994) 370:295–297.
   PubMed Web of Science ®Google Scholar
• BROWN DR, WONG B-S, HAFIZ F, CLIVE C, HAS WELL SJ, JONES IM: Normal prion protein has an acitivity like that of superoxide dismutase. Biochem. (1999) 344:1–5.
   Google Scholar
• KUWAHARA C, TAKEUCHI AM, NISHIMURA T et at Prions prevent neuronal cell-line death. Nature (1999) 400:225–226.
   PubMed Web of Science ®Google Scholar
• BROWN DR, QIN K, HEWS JW et at The cellular prion protein binds copper in vivo. Nature (1997) 390:684–687.
   PubMed Web of Science ®Google Scholar
• PAN K-M, BALDWIN M, NGUYEN J et at Conversion of a-helices into I3-sheets features in the formation of the scarpie prion proteins. Proc. Nati Acad. Sci. USA (1993) 90:10962–10966.
   PubMedGoogle Scholar
• TELLING GC, SCOTT M, MASTRIANNI J et al.: Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell (1995) 83:79–90.
   PubMed Web of Science ®Google Scholar
• TELLING GC, PARCHI P, DEARMOND SJ et al.: Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science (1996) 274:2079–2082.
   PubMed Web of Science ®Google Scholar
• SAFAR J, WILLE H, ITRI Vet al.: Eight prion strains have PrPSc molecules with different conformations. Nature Med. (1998) 4:1157–1165.
   Google Scholar
• KLEIN MA, FRIGG R, FLECHSIG E et at A crucial role for B cells in neuroinvasive scrapie. Nature (1997) 390:687–690.
   PubMed Web of Science ®Google Scholar
• •The first demonstration that B lymphocytes play a role in disease pathogenesis after peripheral inoculation of prions.
   Google Scholar
• KLEIN M, FRIGG R, RAEBER A et at PrP expression in B-lymphocytes is not required for prion neuroinvasion. Nature Med. (1998) 4:1429–1433.
   PubMedGoogle Scholar
• LASMEZAS CI, DESLYS J-P, ROBAIN O et al.: Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science (1997) 275:402–405.
   PubMedGoogle Scholar
• FORLONI G, TAGLIAVINI F, BUGIANI O, SALMONA M: Amyloid in Alzheimer's disease and prion-related encephalopathies: studies with synthetic peptides. Prog. Neurobiol (1996) 49:287–315.
   PubMedGoogle Scholar
• KUNZ B, SANDMEIER E, CHRISTEN P: Neurotoxocity of prion peptide 106-126 not confirmed. FEBS Lett. (1999) 458:65–68.
   PubMedGoogle Scholar
• LARNER AJ, SOFRONIEW MV: Mechanisms of cellular damage and recovery. In: Handbook of neurological rehabilitation (2nd edition). Greenwood R, Barnes MP, McMillan TM, Ward CD (Eds), Psychology Press, London (2002):71–98.
   Google Scholar
• MILHAVET O, LEHMANN S: Oxidative stess and the prion protein in transmissible spongiform encephalopathies. Brain Res. Brain Res. Rev. (2002) 38:328–339.
   PubMed Web of Science ®Google Scholar
• LEBLANC A: Unraveling the controversy of human prion protein diseases. In: Handbook of the Aging Brain. Wang E, Snyder DS (Eds), Academic, San Diego (1998):201–221.
   Google Scholar
• DORANDEAU A, WINGERTSMANN L, CHRE.TIEN F et at Neuronal apoptosis in fatal familial insomnia. Brain Pathol. (1998) 8:531–537.
   Google Scholar
• GRAY F, CHRE.TIEN F, ADLE-BIASSETTE H et al: Neuronal apoptosis in Creutzfeldt-Jakob disease. J. Neuropathol. Exp. Neurol. (1999) 58:321–328.
   PubMedGoogle Scholar
• BROWN DR, SCHMIDT B, KRETZSCHMAR HA: Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature (1996) 380:345–347.
   PubMed Web of Science ®Google Scholar
• HEPPNER FL, PRINZ M, AGUZZI A: Pathogenesis of prion diseases: possible implications of microglial cells. Prog. Brain Res. (2001) 132:737–750.
   PubMedGoogle Scholar
• REZAIE P, LANTOS PL: Microglia and the pathogenesis of spongiform encephalopathies. Brain Res. Brain Res. Rev. (2001) 35:55–72.
   PubMed Web of Science ®Google Scholar
• FARQUHAR C, DICKINSON A, BRUCE M: Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet (1999) 353:117.
   PubMed Web of Science ®Google Scholar
• DEALLER S: Post-exposure prophylaxis after accidental prion inoculation. Lancet (1998) 351:600.
   PubMedGoogle Scholar
• WONG C, XIONG LW, HORIUCHI M et al.: Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO (2001) 20:377–386.
   PubMed Web of Science ®Google Scholar
• SUPATTAPONE S, NGUYEN HOB, COHEN FE, PRUSINER SB, SCOTT MR: Elimination of prions by branched polyamines and implications for therapeutics. Proc. Nati Acad. Sci. USA (1999) 96:14529–14534.
   PubMed Web of Science ®Google Scholar
• PERETZ D, WILLIAMSON RA, KANEKO K et al.: Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature (2001) 412:739–743.
   PubMed Web of Science ®Google Scholar
• •Demonstration that specific antiprion antibodies can block prion propagation within cells.
   Google Scholar
• HEPPNER FL, MUSAHL C, ARRIGHI I et at Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science (2001) 294:178–182.
   PubMed Web of Science ®Google Scholar
• •Demonstration that specific antiprion antibodies can block prion propagation within cells.
   Google Scholar
• SOLOMON B, KOPPEL R, HANAN E, KATZAV T: Monoclonal antibodies inhibit M vitro fibrillar aggregation of the Alzheimer 13-amyloid peptide. Proc. Natl. Acad. Sci. USA (1996) 93:452–455.
   PubMed Web of Science ®Google Scholar
• BARD F, CANNON C, BARBOUR R et at Peripherally administered antibodies against amyloid 13-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nature Med. (2000) 6:916–919.
   PubMed Web of Science ®Google Scholar
• SOTO C, KASCSAK RJ, SABORIO GP et al.: Reversion of prion protein conformational changes by synthetic b-sheet breaker peptides. Lancet (2000) 355:192–197.
   PubMed Web of Science ®Google Scholar
• SCHENK D, BARBOUR R, DUNN W et al.: Immunization with amyloid-I3 attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400:173–177.
   PubMed Web of Science ®Google Scholar
• WEINER HL, LEMERE CA, MARON R et al.: Nasal administration of amyloid-I3 peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. (2000) 48:567–579.
   PubMed Web of Science ®Google Scholar
• JANUS C, PEARSON J, MCLAURIN J et al.: A13 peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2000) 408:979–982.
   PubMed Web of Science ®Google Scholar
• MORGAN D, DIAMOND DM, GOTTSCHALL PE et al.: A13 peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2000) 408:982–985.
   PubMed Web of Science ®Google Scholar
• SIGURDSSON EM, BROWN DR, DANIELS M et al.: Immunization delays the onset of prion disease in mice. Am. J. Pathol. (2002) 161:13–17.
   PubMed Web of Science ®Google Scholar
• •Use of PrP peptides as a vaccine to delay the onset of prion disease by induction of anti-PrP antibodies.
   Google Scholar
• KORTH C, MAY BC, COHEN FC, PRUSINER SB: Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Nati Acad. ScL USA (2001) 98:9836–9841.
   PubMed Web of Science ®Google Scholar
• ••Demonstration that quinacrine andchlorpromazine, amongst others, can inhibit prion propagation in cell cultures. Since these two drugs are already in clinical use for other indications, with well characterised side effect profiles, clinical trials in prion disease have commenced.
   Google Scholar
• AGUZZI A, COLLINGE J: Post-exposure prophylaxis after accidental prion inoculation. Lancet (1997) 350:1519–1520.
   PubMedGoogle Scholar
• KORTH C, STIERLI B, STREIT P et al: Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature (1997) 390:74–77.
   PubMed Web of Science ®Google Scholar
• CAUGHEY B: Transmissible spongiform encephalopathies, amyloidoses and yeast prions: common threads? Nature Med. (2000) 6:751–754.
   Google Scholar
• PRIOLA S, RAINES A, CAUGHEY WS: Porphyrin and phthalocyanine antiscrapie compounds. Science (2000) 287:1503–1506.
   PubMed Web of Science ®Google Scholar
• CAUGHEY B: Interactions between prion protein isoforms: the kiss of death? Trends Biochem. Sci. (2001) 26:235–242.
   Google Scholar
• MANTHORPE M, FAGNANI R, SKAPER SD, VARON S: An automated colorimetric microassay for neuronotrophic factors. Dev. Brain Res. (1986) 25:191–198.
   Google Scholar
• SMITH MA, ATWOOD CS, JOSEPH JA, PERRY G: Predicting the failure of amyloid-I3 vaccine. Lancet (2002) 359: 1864-1865.
   Google Scholar
• ASHWELL S: Caspases: recent advances in small molecule inhibitors. Exp. Opin. Then Patents (2001) 11 (10) :1593–1603.
   Web of Science ®Google Scholar
• LARNER AJ: Poly(ADP-ribose) polymerase inhibitors in the prevention of neuronal cell death. Exp. Opin. Then Patents (2002) 12(4):481–487.
   Google Scholar
• OTTO M, BOEKHOFF I, RATZKA P et al: First therapeutic experience with flupirtine in patients with Creutzfeldt-Jakob disease. J. Neurol. (1998) 245:486 (abstract P549).
   Google Scholar
• LARNER AJ: Neuronal apoptosis as a therapeutic target in neurodegenerative disease. Exp. Opin. Then Patents (2000) 10(10):1493–1518.
   Web of Science ®Google Scholar
• SZALLASI A, FOWLER CJ: After a decade of intravesical vanilloid therapy: still more questions than answers. Lancet Neurology (2002) 1:167–172.
   PubMed Web of Science ®Google Scholar
• MUQIT MMK, FEANY MB: Modelling neurodegenerative diseases in Drosophila: a fruitful approach? Nat. Rev Neurosci. (2002) 3:237-243. ao. TARNOPOLSKY MA, BEAL MF: Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol. (2001) 49:561–574.
   Google Scholar
• SCHNEIDER C, BECK M, GEORGE A et al.: Creatine monohydrate in proximal myotonic myopathy (PROMM): a double-blind, placebo-controlled clinical study. Neurology (2002) 58 (supp13):A225 (abstract P03.126).
   Google Scholar
• QIZILBASH N: Evidence-based interventions. In: Evidence-based dementia practice. Qizilbash N, Schneider LS, Chui H, Tariot P, Brodaty H, Kaye J, Erkinjuntti T (Eds), Blackwell, Oxford (2002):31–41.
   Google Scholar
• LARNER Al: Alzheimer's disease: targets for drug development. Mini-reviews in Medicinal Chemistry (2002) 2(1): 1–9.
   PubMedGoogle Scholar
• CONDE S: P-Amyloid peptide as a target for treatment of Alzheimer's disease. Exp. Opin. Ther. Patents (2002) 12 (4):503–512.
   Google Scholar
• EMRE M: Drugs in development and experimental approaches. In: Evidence-based dementia practice. Qizilbash N, Schneider LS, Chui H, Tariot P, Brodaty H, Kaye J, Erkinjuntti T (Eds), Blackwell, Oxford (2002):447–457.
   Google Scholar
• COLLINS SJ, LEWIS V, BRAZIER M, HILL AF, FLETCHER A, MASTERS CL: Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann. Neurol. (2002) 52:503–506.
   PubMed Web of Science ®Google Scholar
• MULLER WE, LAPLANCHE JL, USHIJIMA H, SCHRODER HC: Novel approaches in diagnosis and therapy of Creutzfeldt-Jakob disease. Mech. Ageing Dev. (2001) 116:193–218.
   Google Scholar
• OTTO M, RATZKA P, DOEHLINGER S et al.: Efficacy of flupirtine on cognitive function in patients with Creutzfeldt-Jakob disease. Neurobiol. Aging (2002) 23(1S):5131-5132 (abstract 497).
   Google Scholar